Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TrHCROSS
- Development stage
- Unknown
- Lead developer
- i+Med
- Administration
- Intraarticular
01
Overview
TrHCROSS is a cross-linked hyaluronic acid (HA) viscosupplement developed by TRB Chemedica for the treatment of knee osteoarthritis. Administered as a single intra-articular injection, it is designed to restore the viscoelasticity of the synovial fluid, which is typically diminished in osteoarthritic joints. The cross-linking of the HA chains increases the molecular weight and residence time of the product within the joint space, providing prolonged lubrication and mechanical cushioning. Clinical evaluation focuses on its safety and efficacy in reducing pain and improving functional outcomes compared to other HA products.
- Brand names
- TrHCROSS
- Other names
- cross-linked hyaluronic acid
Beyond the preview
Go deeper on TrHCROSS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TrHCROSS.